MARKET

BLUE

BLUE

Bluebird Bio Inc
NASDAQ
0.9229
-0.0477
-4.91%
After Hours: 0.9380 +0.0151 +1.64% 17:34 04/24 EDT
OPEN
0.9900
PREV CLOSE
0.9706
HIGH
1.020
LOW
0.9125
VOLUME
8.14M
TURNOVER
0
52 WEEK HIGH
5.53
52 WEEK LOW
0.8790
MARKET CAP
177.88M
P/E (TTM)
-1.2395
1D
5D
1M
3M
1Y
5Y
Crispr Therapeutics: Now Is The Time To Buy
CRISPR Therapeutics' stock has declined in value despite recent FDA approvals for its groundbreaking gene editing technology. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR has enough cash on hand to fund operations for at least 24 months.
Seeking Alpha · 7h ago
Hercules Capital: Winning Option In The Financial Services Space
Seeking Alpha · 7h ago
Weekly Report: what happened at BLUE last week (0415-0419)?
Weekly Report · 2d ago
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
NASDAQ · 5d ago
BUZZ-bluebird delays filing of Q1 and 2023 reports, shares fall
Bluebird bio's shares fall 3% to 96 cents in extended trading. Gene therapy developer delays filing of Q1 and 2023 reports. Company says delays due to work required to restate financial statements. Company's stock down 70.8% in the past 12 months.
Reuters · 04/16 21:38
Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
Benzinga · 04/16 20:26
BLUEBIRD BIO INC - ANTICIPATES IT WILL BE DELAYED IN FILING ITS QUARTERLY REPORT ON FORM 10-Q FOR THE FIRST QUARTER OF 2024
Reuters · 04/16 20:08
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
NASDAQ · 04/16 18:05
More
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).

Webull offers bluebird bio Inc stock information, including NASDAQ: BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.